Routine noninvasive prenatal screening for fetal Rh D in maternal plasma-A 2-year experience from a single center in Belgium.
HDN
immunohematology (RBC serology, blood groups)
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
28
02
2022
received:
27
11
2021
accepted:
01
03
2022
pubmed:
31
3
2022
medline:
11
5
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
Hemolytic disease of the fetus and newborn (HDFN) due to rhesus D (RhD) immunization is a potentially life-threatening situation for which use of Rh Immunoglobulin (RhIg) has decreased risk drastically. Determination of fetal RHD on maternal plasma can be used to restrict prenatal RhIg administration to women carrying an RhD-positive child, avoiding unnecessary administration of blood-derived products. The aim of this study is to determine the performance of fetal RHD typing in our center. We prospectively collected 205 fetal RHD and 127 serological cord blood RhD data from RhD-negative women starting at 11 weeks of pregnancy (from October 2019 to October 2021). Real-time polymerase chain reaction targeting RHD exon 5 and 7 was used, similar to the screening program in The Netherlands, supplemented with an amplification control (beta-actin; ACTB) and a sex determination marker located on the Y-chromosome (SRY gene). Fetal RHD testing reached a sensitivity and specificity of 100%. No false-negative nor false-positive results were reported. Inconclusive results (6%, 13/205) were due to weak amplification in 10 cases, a maternal RHD variant in 2 cases (RHD*01N.71 and partial DVI), and a fetal RHD variant (partial DVI) in 1 case. Unnecessary administration of RhIg prophylaxis was avoided in 33% of cases and on the other hand was administered in one case (fetal partial DVI) which would have been missed with cord blood serology. This study demonstrates the high accuracy of routine prenatal fetal RHD gene screening after 11 weeks of pregnancy, encouraging routine clinical practice.
Sections du résumé
BACKGROUND
Hemolytic disease of the fetus and newborn (HDFN) due to rhesus D (RhD) immunization is a potentially life-threatening situation for which use of Rh Immunoglobulin (RhIg) has decreased risk drastically. Determination of fetal RHD on maternal plasma can be used to restrict prenatal RhIg administration to women carrying an RhD-positive child, avoiding unnecessary administration of blood-derived products.
STUDY DESIGN AND METHODS
The aim of this study is to determine the performance of fetal RHD typing in our center. We prospectively collected 205 fetal RHD and 127 serological cord blood RhD data from RhD-negative women starting at 11 weeks of pregnancy (from October 2019 to October 2021). Real-time polymerase chain reaction targeting RHD exon 5 and 7 was used, similar to the screening program in The Netherlands, supplemented with an amplification control (beta-actin; ACTB) and a sex determination marker located on the Y-chromosome (SRY gene).
RESULTS
Fetal RHD testing reached a sensitivity and specificity of 100%. No false-negative nor false-positive results were reported. Inconclusive results (6%, 13/205) were due to weak amplification in 10 cases, a maternal RHD variant in 2 cases (RHD*01N.71 and partial DVI), and a fetal RHD variant (partial DVI) in 1 case. Unnecessary administration of RhIg prophylaxis was avoided in 33% of cases and on the other hand was administered in one case (fetal partial DVI) which would have been missed with cord blood serology.
DISCUSSION
This study demonstrates the high accuracy of routine prenatal fetal RHD gene screening after 11 weeks of pregnancy, encouraging routine clinical practice.
Substances chimiques
Rh-Hr Blood-Group System
0
Rho(D) Immune Globulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1103-1109Informations de copyright
© 2022 AABB.
Références
Van der Schoot E, de Haas M, Bach CF. Genotyping to prevent Rh disease: has the time come? Curr Opin Hematol. 2017;24(6):544-50.
Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000;14:44-61.
Hirose TG, Mays DA. The safety of RhIG in the prevention of haemolytic disease of the newborn. J Obstet Gynaecol. 2007;27:545-57.
de Haas M, Finning K, Massey E, Roberts DJ. Anti-D prophylaxis: past, present and future. Transfus Med. 2014;24:1-7.
Crowther C, Middelton P, McBain RD. Anti-D administration in pregnancy for preventing rhesus allo-immunization (Cochrane review). Cochrane Database Syst Rev. 2013;2:CD000020.
Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CWG, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485-7.
Faas BHW, Beuling EA, Christiaens GCML, von dem Borne AEGK, van der School C. Detection of fetal RHD-specific sequences in maternal plasma. Lancet. 1998;352:1196.
Lo YMD, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med. 1998;339:1734-8.
van der Schoot C, Soussan AA, Koelewijn J, Bonsel G, Paget-Christiaens LG, de Haas M. Noninvasive antenatal RHD typing. Transfus Clin Biol. 2006;13:53-7.
Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ. 2008;336:816-8.
Müller SP, Bartels I, Stein W, Emons G, Gutensohn K, Köhler M, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion. 2008;48:2292-301.
Bach CF, Steffensen R, Christiansen M, Rudby M, Jakobsen MA, Jakobsen TR, et al. Routine noninvasive prenatal screening for fetal RHD in plasma of RHD-negative pregnant women - 2 years of screening experience from Denmark. Prenat Diagn. 2014;34:1000-5.
de Haas M, Thurik FF, van der Ploeg CPB, Veldhuisen B, Hirschberg H, Soussan AA, et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in The Netherlands. BMJ. 2016;355:i5789.
Haimila K, Sulin K, Kuosmanen M, Sareneva I, Korhonen A, Natunen S, et al. Targeted antenatal anti-D prophylaxis program for RHD-negative pregnant women - outcome of the first two years of national program in Finland. Acta Obstet Gynecol Scand. 2017;96:1228-33.
Minon J-M, Gerard C, Senterre J-M, Schaaps JP, Foidart JM. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion. 2008;48:373-81.
Finning K, Martin P, Deniela G. A clinical service in the UKto predict fetal Rh (rhesus) D blood using free fetal DNA in maternal plasma. Ann N Y Acad Sci. 2004;1022:119-23.
Gautier E, Benachi A, Giovangrandi Y, Ernault P, Olivi M, Gaillon T, et al. Fetal RHD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol. 2005;192(3):666-9.
Avent ND, Reid ME. The Rh blood group system: a review. Blood. 2000;95:375-87.
Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion. 2002;42:1079-85.
Grootkerk-Tax MG, Soussan AA, de Haas M, Maaskant-van Wijk P, van der Schoot C. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion. 2006;46:2142-8.
Rodriguez-Martinez B, Sarasola-Diez E, Achalandabaso E, Garcia-Barcina MJ. Optimized short digestion protocol for free fetal DNA detection using methylation-dependent markers. LaboratoriumsMedizin. 2017;41(4):195-203.
Clausen FB, Hellberg Å, Bein G. Recommendation for validation and quality assurance of non-invasive prenatal testing for foetal blood groups and implications for IVD risk classification according to EU regulations. Vox Sang. 2021;117:15-165.
Wikman A, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol. 2012;120:1-7.
Chitty LS, Finning K, Wade A, Soothill P, Martin B, Oxenford K, et al. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ. 2014;349:g5243.
Jensen MPS, Damjaer MB, Clausen FB, Ali HA, Hare KJ, Dziegiel MH, et al. Targeted rhesus immunoglobulin for RhD-negative women undergoing an induced abortion: a clinical pilot study. Acta Obstet Gynaecol Scand. 2019;98:1164-71.